News &amp; Updates

The use of lubiprostone as an adjunct therapy for bowel preparation results in better odds of excellent quality prep, with an acceptable safety profile, a study has shown.

Three-drug combo helps manage sinusitis in paediatric cystic fibrosis

Treatment with the fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor may reduce the severity of chronic rhinosinusitis in children with cystic fibrosis, as shown in a retrospective study.

Donanemab shows long-term benefits in early symptomatic AD

Treatment with donanemab continues to show increasing clinical benefits in patients with early symptomatic Alzheimer’s disease (AD), according to the phase III TRAILBLAZER‐ALZ 2 long-term extension (LTE) study presented at AAIC 2026.

Is a two-shot protocol sufficient for ovarian stimulation?

A novel two-injection ovarian stimulation strategy yielded a comparable number of mature (MII) oocytes to a conventional protocol but did not demonstrate noninferiority, according to a recent study presented at ESHRE 2026.

HK public hospital experience: Earlier use of 2L therapies improves maternal outcomes, despite rise in massive primary PPH

A study conducted at a single public maternity unit in Hong Kong reports a 67 percent increase in massive primary postpartum haemorrhage (PPH) between 2006–2011 and 2017–2022, as well as considerable improvements in maternal outcomes, such as lower blood loss and hysterectomy rate, owing to increased use of second-line (2L) therapies.

29 Aug 2026

10 years after CAR T-cell therapy: 32–47 percent OS in R/R B-cell NHL

A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.

29 Aug 2026

COVID-19 vaccination protects against postacute sequelae for months

28 Aug 2026 by

Vaccination against COVID-19 lowers the risk of developing long COVID symptoms, and this protective effect persists for up to 7 months following vaccination, as shown in a retrospective study.

Coronary artery calcium guides statin use eligibility

A recent study suggests the clinical value of coronary artery calcium (CAC) when statin treatment decisions are uncertain, especially among individuals with borderline predicted risk.

Daily supplementation helps normalize vitamin D status in very preterm infants

28 Aug 2026 by

Very preterm infants are at increased risk of vitamin D deficiency (VDD), defined as 25(OH)D <20 ng/mL, a Thai study has found.